Amylyx Pharmaceuticals (AMLX) Retained Earnings (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Retained Earnings of $240000.0 for Q1 2026, up 100.04% year-over-year from $119977.6 in Q1 2025, and up 100.03% quarter-over-quarter from -$751.4 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Retained Earnings (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Retained Earnings history runs 6 years deep, the most recent figure standing at $240000.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 100.04% year-over-year to $240000.0; the TTM figure through Mar 2026 stood at $240000.0 (up 100.04% YoY), while the FY2025 annual figure was -$751.4 million, down 23.86% from the prior year.
- Retained Earnings for Q1 2026 stood at $240000.0, up from -$751.4 million in the prior quarter.
- The five-year high for Retained Earnings was $551000.0 in Q2 2025, with the low at -$751.4 million in Q4 2025.
- The 5-year median for Retained Earnings is -$311.5 million (2022), against an average of -$284.7 million.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings plunged 3935877.78% in 2022, then jumped 668.04% in 2025.
- Amylyx Pharmaceuticals' Retained Earnings stood at -$354.2 million in 2022, then soared by 100.06% to $197000.0 in 2023, then sank by 308065.48% to -$606.7 million in 2024, then dropped by 23.86% to -$751.4 million in 2025, then jumped by 100.03% to $240000.0 in 2026.
- Business Quant data shows AMLX's Retained Earnings at $240000.0 in Q1 2026, -$751.4 million in Q4 2025, and -$718.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 3.75 Bn |
| 10 | Amylyx Pharmaceuticals | 4.34 Bn | 4.34 Bn | - | -836.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -836.13 Mn |
| Mar 31, 2026 | 240,000.00 |
| Dec 31, 2025 | -751.43 Mn |
| Sep 30, 2025 | -718.43 Mn |
| Jun 30, 2025 | 551,000.00 |
| Mar 31, 2025 | -642.60 Mn |
| Dec 31, 2024 | -606.69 Mn |
| Sep 30, 2024 | -569.15 Mn |
| Jun 30, 2024 | -97,000.00 |
| Mar 31, 2024 | -77,000.00 |
| Dec 31, 2023 | 197,000.00 |
| Sep 30, 2023 | -151,000.00 |
| Jun 30, 2023 | -330.57 Mn |
| Mar 31, 2023 | -352.65 Mn |
| Dec 31, 2022 | -354.22 Mn |
| Sep 30, 2022 | -311.50 Mn |
| Jun 30, 2022 | -196,000.00 |
| Mar 31, 2022 | -203.70 Mn |
| Dec 31, 2021 | 9,000.00 |